How are ambiguities in the Learningrx release agreement construed?
Learningrx Franchise · 2025 FDDAnswer from 2025 FDD Document
The terms of this Release arose from negotiations and discussions between the parties.
Accordingly, no claimed ambiguity in this Release shall be construed against any party claimed to have drafted or proposed the language in question.
Source: Item 22 — CONTRACTS (FDD page 54)
What This Means (2025 FDD)
According to the 2025 Learningrx Franchise Disclosure Document, any ambiguities within the release agreement will not be interpreted against the party who drafted or proposed the language. This means that if there is a dispute over the meaning of a clause in the release, the franchisee cannot argue that the ambiguity should be interpreted in their favor simply because Learningrx (or the franchisee) wrote the clause. This clause promotes neutrality in interpreting the agreement.
This type of clause is relatively common in franchise agreements. It aims to create a level playing field in the interpretation of the contract, preventing one party from benefiting from ambiguities simply because they did not draft the language. It encourages both parties to carefully review and understand the terms before signing.
For a prospective Learningrx franchisee, this means it is crucial to fully understand the implications of the release agreement before signing. If there are any unclear terms, the franchisee should seek clarification from Learningrx or obtain independent legal advice. This clause underscores the importance of due diligence and careful review of all legal documents associated with the franchise agreement.